{"id":"ff-inhalation-powder","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone furoate is a potent inhaled corticosteroid designed for pulmonary delivery. It binds to glucocorticoid receptors in the airways and lungs, suppressing inflammatory cell recruitment and reducing production of inflammatory mediators, thereby decreasing airway inflammation and improving airflow obstruction in respiratory diseases.","oneSentence":"FF (fluticasone furoate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:44:23.233Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT05168995","phase":"","title":"Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control","status":"COMPLETED","sponsor":"Chiesi Italia","startDate":"2022-04-12","conditions":"Asthma","enrollment":620},{"nctId":"NCT07282886","phase":"PHASE2","title":"VENTURI (VENTilation Using Respiratory Imaging)","status":"NOT_YET_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2026-03-15","conditions":"Asthma","enrollment":20},{"nctId":"NCT05535972","phase":"PHASE4","title":"To Evaluate Real-World Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol (FF/UMEC/VI) in a Single Inhaler (Trelegy Ellipta) in Participants With Symptomatic COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-14","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":463},{"nctId":"NCT05743608","phase":"","title":"NEXThaleR Real-world Study Assessing the EffectivenesS of BDP/FF/G Fixed triPle cOmbiNation on Symptom scorEs in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Hungary Ltd.","startDate":"2023-03-29","conditions":"COPD","enrollment":1336},{"nctId":"NCT03248128","phase":"PHASE3","title":"Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-20","conditions":"Asthma","enrollment":906},{"nctId":"NCT02889809","phase":"PHASE4","title":"Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-07-10","conditions":"Asthma","enrollment":477},{"nctId":"NCT04876677","phase":"PHASE3","title":"Functional Respiratory Imaging Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-05-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":25},{"nctId":"NCT03474081","phase":"PHASE4","title":"A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-03-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":800},{"nctId":"NCT02924688","phase":"PHASE3","title":"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-13","conditions":"Asthma","enrollment":2436},{"nctId":"NCT03622112","phase":"PHASE2","title":"A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-01-02","conditions":"Asthma","enrollment":808},{"nctId":"NCT03467425","phase":"PHASE4","title":"INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-04-11","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":3109},{"nctId":"NCT02991859","phase":"PHASE2","title":"Phase 2a, AMP Challenge, Dose Escalation Study to Assess the Dose Response for Topical Efficacy and Systemic Activity in Asthmatic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-09","conditions":"Asthma","enrollment":56},{"nctId":"NCT02573870","phase":"PHASE2","title":"Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-12-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":63},{"nctId":"NCT03184987","phase":"PHASE3","title":"A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-06-22","conditions":"Asthma","enrollment":111},{"nctId":"NCT02483975","phase":"PHASE3","title":"Effect of Fluticasone Furoate Inhalation Powder on the Hypothalamic-pituitary-adrenocortical Axis of Children Aged 5-11 Years With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-09","conditions":"Asthma","enrollment":111},{"nctId":"NCT03949842","phase":"PHASE4","title":"Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-06-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT02729051","phase":"PHASE3","title":"Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-06-29","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1055},{"nctId":"NCT01957150","phase":"PHASE4","title":"Study Evaluating the Effect of Fluticasone Furoate/ Vilanterol (FF/VI) Inhalation Powder Compared With Vilanterol (VI) Inhalation Powder on Bone Mineral Density (BMD) in Subjects With Chronic Obstructive Pulmonary Disease (COPD).","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-01-28","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":283},{"nctId":"NCT03376932","phase":"PHASE3","title":"Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2019-01-18","conditions":"Asthma","enrollment":""},{"nctId":"NCT01706198","phase":"PHASE3","title":"An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-01","conditions":"Asthma","enrollment":4233},{"nctId":"NCT02446418","phase":"PHASE3","title":"A Study to Compare the Efficacy of Fluticasone Furoate/Vilanterol Inhalation Powder With Usual Inhaled Corticosteroids (ICS)/Long Acting Beta Agonists (LABA) in Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-07-09","conditions":"Asthma","enrollment":423},{"nctId":"NCT02796677","phase":"PHASE3","title":"AMPLIFY - D6571C00001 Duaklir USA Phase III Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-07-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1595},{"nctId":"NCT02164513","phase":"PHASE3","title":"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":10355},{"nctId":"NCT01342913","phase":"PHASE3","title":"A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP))","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":528},{"nctId":"NCT01017952","phase":"PHASE3","title":"A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1635},{"nctId":"NCT02301975","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-03-01","conditions":"Asthma","enrollment":1526},{"nctId":"NCT02218723","phase":"PHASE1","title":"Pharmacokinetic Profile of Four Formulations of Fluticasone Furoate (FF) Using Unit Dose Dry Powder Inhaler (UD-DPI) Compared With FF ELLIPTA® Presentation","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-10-28","conditions":"Asthma","enrollment":30},{"nctId":"NCT02345161","phase":"PHASE3","title":"A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-01-23","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1811},{"nctId":"NCT01053988","phase":"PHASE3","title":"A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-05","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1031},{"nctId":"NCT01706328","phase":"PHASE3","title":"A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":828},{"nctId":"NCT00862394","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2009-02","conditions":"Asthma","enrollment":783},{"nctId":"NCT01323621","phase":"PHASE3","title":"Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":512},{"nctId":"NCT01395888","phase":"PHASE3","title":"A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":260},{"nctId":"NCT02787967","phase":"PHASE2","title":"Clinical Pharmacology of 35/4 NEXThaler® in Children 5-11 Years Old","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-08","conditions":"Asthma","enrollment":26},{"nctId":"NCT02105974","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-07","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1621},{"nctId":"NCT01686633","phase":"PHASE3","title":"An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol (FF/VI) 200/25 Microgram (mcg) , FF/VI 100/25 mcg, and FF 100 mcg in Adults and Adolescents With Persistent Asthma.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-09-20","conditions":"Asthma","enrollment":1040},{"nctId":"NCT01054885","phase":"PHASE3","title":"Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-19","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1226},{"nctId":"NCT02502734","phase":"PHASE3","title":"Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-09-07","conditions":"Asthma","enrollment":60},{"nctId":"NCT01072149","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-01-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":54},{"nctId":"NCT01627327","phase":"PHASE3","title":"Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared With Tiotropium Bromide Inhalation Powder 18mcg Once Daily in Subjects With COPD Who Have or Are At Risk for Co-morbid Cardiovascular Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-04-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":623},{"nctId":"NCT01009463","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-25","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":1626},{"nctId":"NCT01957163","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":619},{"nctId":"NCT01323634","phase":"PHASE3","title":"Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-03-18","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":519},{"nctId":"NCT02164539","phase":"PHASE2","title":"Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-07-01","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":338},{"nctId":"NCT01691547","phase":"PHASE1","title":"A Study to Assess the Systemic Exposure, Systemic Pharmacodynamics and Safety and Tolerability of FluticasoneFuroate, Umeclidinium and Vilanterol in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-17","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":44},{"nctId":"NCT01711463","phase":"PHASE1","title":"Relovair PD PK in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-12-05","conditions":"Asthma","enrollment":16},{"nctId":"NCT01000597","phase":"PHASE1","title":"Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate is Processed by the Body in Healthy Caucasian, Japanese, Korean and Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-17","conditions":"Asthma","enrollment":80},{"nctId":"NCT01213849","phase":"PHASE1","title":"Dose Proportionality Study: Blood Levels of Fluticasone Furoate (FF) and Vilanterol (VI) Following Different Doses of FF/VI Via an Inhaler","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-04","conditions":"Asthma","enrollment":24},{"nctId":"NCT01669070","phase":"PHASE1","title":"A Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate Inhalation Powder Administered by Novel Dry Powder Inhaler (NDPI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-08-15","conditions":"Asthma","enrollment":36},{"nctId":"NCT01485445","phase":"PHASE1","title":"Bioequivalence Study to Compare Fluticasone Furoate (FF) 1-strip Inhaler With FF 2-strip Inhaler and With FF/Vilanterol Combination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-12-21","conditions":"Asthma","enrollment":30},{"nctId":"NCT01299558","phase":"PHASE1","title":"Study to Look at and Compare How Inhaled and Intravenous Fluticasone Furoate and GW642444 Are Processed by the Body in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-05-17","conditions":"Asthma","enrollment":16},{"nctId":"NCT01725685","phase":"PHASE1","title":"To Investigate the Pharmacokinetics and Safety of Fluticasone Furoate (FF)/ Umeclidinium (UMEC) Combination Compared With FF and UMEC Monotherapies in Adult Healthy Volunteers Using a Dry Powder Inhaler (DPI)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-11-08","conditions":"Asthma","enrollment":18},{"nctId":"NCT01165125","phase":"PHASE1","title":"A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-01","conditions":"Asthma","enrollment":18},{"nctId":"NCT01209026","phase":"PHASE1","title":"Corrected QT (QTc) Study With Flucticasone Furoate and GW642444","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06-23","conditions":"Asthma","enrollment":85},{"nctId":"NCT01551758","phase":"PHASE3","title":"A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-03-13","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":2802},{"nctId":"NCT01563029","phase":"PHASE2","title":"A Dose-ranging Study of Fluticasone Furoate (FF)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-03-28","conditions":"Asthma","enrollment":597},{"nctId":"NCT02666287","phase":"PHASE1","title":"GSK961081 Alone and With Fluticasone Furoate (FF), Phase 1 (Ph1), Single Dose Regimen (SD), Repeat Dose Regimen (RD), Pharmacokinetic (PK) Study in Healthy Volunteer (HV)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-01-27","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT01894386","phase":"PHASE1","title":"Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-07-15","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":48},{"nctId":"NCT01837316","phase":"PHASE1","title":"A Study to Assess the Bronchodilator Effect of a Single Dose of Fluticasone Furoate (FF)/ Vilanterol (VI) 100/25 Micrograms (mcg) Combination When Administered in Adult Patients With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10-21","conditions":"Asthma","enrollment":32},{"nctId":"NCT01345916","phase":"PHASE3","title":"Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-03","conditions":"Asthma","enrollment":932},{"nctId":"NCT01854645","phase":"PHASE3","title":"Efficacy and Safety of PT003, PT005, and PT001 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD); (PINNACLE 1)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":2103},{"nctId":"NCT02119286","phase":"PHASE3","title":"Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-10","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":620},{"nctId":"NCT01970878","phase":"PHASE3","title":"Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)","status":"COMPLETED","sponsor":"Pearl Therapeutics, Inc.","startDate":"2013-11","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":892},{"nctId":"NCT01498679","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01","conditions":"Asthma","enrollment":311},{"nctId":"NCT02837380","phase":"PHASE1","title":"A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-09","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":16},{"nctId":"NCT01086410","phase":"PHASE3","title":"Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-03","conditions":"Asthma","enrollment":185},{"nctId":"NCT01287065","phase":"PHASE2","title":"A Study in Asthmatic Patients to Determine if There is Any Difference in Dosing With Fluticasone Furoate/Vilanterol Inhalation Powder in the Morning or Evening on Lung Function","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Asthma","enrollment":26},{"nctId":"NCT01192191","phase":"PHASE3","title":"A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-08","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":187},{"nctId":"NCT01453023","phase":"PHASE2","title":"Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-10","conditions":"Asthma","enrollment":26},{"nctId":"NCT01244984","phase":"PHASE3","title":"A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07","conditions":"Asthma","enrollment":243},{"nctId":"NCT01808339","phase":"PHASE2","title":"To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03","conditions":"Asthma","enrollment":28},{"nctId":"NCT01498653","phase":"PHASE3","title":"Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Trifenatate in the Treatment of Asthma in Adolescent and Adult Subjects of Asian Ancestry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-01","conditions":"Asthma","enrollment":313},{"nctId":"NCT02731846","phase":"PHASE3","title":"A Study Comparing the Closed Triple Therapy, Open Triple Therapy and a Dual Therapy for Effect on Lung Function in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2016-06","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":""},{"nctId":"NCT01650441","phase":"PHASE2","title":"Study to Assess the Effect of the NEXThaler® Device (DPI - Dry Powder Inhaler) on the Central and Peripheral Airway Dimensions in Asthmatic Patients","status":"COMPLETED","sponsor":"University Hospital, Antwerp","startDate":"2012-04","conditions":"Asthma","enrollment":31},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FF Inhalation Powder","genericName":"FF Inhalation Powder","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"FF (fluticasone furoate) is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors in lung tissue. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}